Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
On Friday, KeyBanc analysts initiated coverage on Solventum (NYSE: SOLV) with a Sector Weight rating. The decision follows Solventum’s spin-off from 3M, which was completed in April 2024. The $13 billion market cap company has shown strong momentum, delivering a 37% return over the past year, though analysts remain cautious as they wait for clearer signs of a sustainable revenue growth turnaround beyond the current 1.3% pace.
Solventum’s management recently outlined a strategy aimed at achieving market growth closer to mid-single-digit figures. Analysts at KeyBanc, however, noted that the current visibility into achieving this goal is limited.
Several factors are seen as potential drivers for margin expansion at Solventum, though some known headwinds remain. Portfolio management is highlighted as a critical component in the company’s strategy moving forward.
The analyst also pointed out that Solventum’s valuation is moderately discounted when compared to its peers, which they believe reflects current growth trends.
In other recent news, Solventum reported mixed results for its first quarter of 2025. The company announced adjusted earnings per share (EPS) of $1.34, which fell short of the forecasted $1.57, while revenue met expectations at $2.1 billion. Despite the earnings miss, Solventum managed to achieve an organic sales growth of 4.3%. Piper Sandler upgraded Solventum’s stock rating from Neutral to Overweight, increasing the price target to $87. This upgrade was influenced by Solventum’s recent first-quarter performance, which exceeded expectations in some areas, and the easing of U.S./China tariffs. Additionally, Solventum’s sale of its Products & Filtration division to Thermo Fisher (NYSE:TMO) for $4.1 billion is anticipated to enhance the company’s capital allocation flexibility. CEO Brian Hansen expressed optimism about the company’s strategic focus and growth potential despite ongoing challenges. The company maintains its full-year EPS guidance of $5.45 to $5.65, expecting organic sales growth of 1.5% to 2.5%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.